SCHEMBL15026144

SCHEMBL15026144

Oc1cc(/C=C/c2ccc(O)c(O)c2)cc(/C=C/c2ccc(O)c(O)c2)c1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.91
CYP3A4 P08684 4/20 0.91
CYP2C9 P11712 4/20 0.91
HIF1A Q16665 4/20 0.91
HSD17B10 Q99714 4/20 0.91
KDM4E B2RXH2 4/20 0.91
ALDH1A1 P00352 4/20 0.91
LMNA P02545 4/20 0.91
MAPT P10636 4/20 0.91
HPGD P15428 4/20 0.91
SMN1; SMN2 Q16637 4/20 0.91
ALOX12 P18054 3/20 0.91
ALOX5 P09917 3/20 0.91
TTR P02766 3/20 0.91
TP53 P04637 3/20 0.91
CYP1A2 P05177 3/20 0.91
MEN1 O00255 3/20 0.91
KMT2A Q03164 3/20 0.91
ALOX15 P16050 3/20 0.91
THPO P40225 3/20 0.91

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1932873 1.00 LCK (0.91) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL29929133 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL43541 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL29754702 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL505561 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL29501290 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
Piceatannol SCHEMBL19953785 0.95 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
SCHEMBL13409618 0.89 LCK (0.72) LCKCYP3A4CYP2C9HIF1AHSD17B10
SCHEMBL31706727 0.88 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10
SCHEMBL30631591 0.88 LCK (1.00) LCKCYP3A4CYP2C9HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF PERSONAL CARE AND NUTRITION GMBH (DE) 2019-07-18 US disclosed
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF PERSONAL CARE AND NUTRITION GMBH (DE) 2019-07-18 US disclosed
EP-3455201-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2019-03-20 EP disclosed
WO-2017194590-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2017-11-16 WO disclosed
WO-2017194590-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2017-11-16 WO disclosed
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN DePuy Synthes Products, Inc. (US) 2017-08-10 US disclosed
US-20140163116-A1 METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE DePuy Synthes Products, LLC (US) 2014-06-12 US disclosed
US-20140057994-A1 COMPOSITIONS COMPRISING SUBSTITUTED PHENOLS AND TOPICAL APPLICATION THEREOF JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-02-27 US disclosed
US-20140057994-A1 COMPOSITIONS COMPRISING SUBSTITUTED PHENOLS AND TOPICAL APPLICATION THEREOF JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-02-27 US disclosed
US-20130150628-A1 PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE DIMAURO THOMAS M (US) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057994-A1 COMPOSITIONS COMPRISING SUBSTITUTED PHENOLS AND TOPICAL APPLICATION THEREOF TYR, S100A4, S100A6 LCK 2037/4885CYP3A4 783/4885CYP2C9 635/4885
US-20130150628-A1 PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE CPT1A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCB1 LCK 4307/4885CYP3A4 40/4885CYP2C9 18/4885
US-20140163116-A1 METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE HDAC5, HDAC6, CPT1A LCK 3096/4885CYP3A4 920/4885CYP2C9 546/4885
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS HPD, HAAO, PAH LCK 1632/4885CYP3A4 14/4885CYP2C9 50/4885
US-20170224637-A1 INTRANSAL DELIVERY OF CURCUMIN FABP7, FABP2, NDUFB5 LCK 4207/4885CYP3A4 3413/4885CYP2C9 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.